International data agrees
January 12, 2022
1,356,022
39,658
6,308
3.39%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Dr John Campbell Episodes Around January 12, 2022
See what was published immediately before and after this episode.
24:33Now PlayingInternational data agrees
YouTube Description
as posted by the channelOmicron is less severe and natural immunity works
Link to free download of my 2 textbooks
Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California
Background
The Omicron (B.1.1.529) variant of SARS-CoV-2 has rapidly achieved global dissemination,
accounting for most infections in the United States by December 2021.
November 30, 2021 to January 1, 2022, Delta v Omicron
Using S gene target failure (SGTF) (99.7%)
Hospital admission
Lengths of hospital stay
Hospital admissions associated with new-onset respiratory symptoms
Intensive care unit (ICU) admission
Mechanical ventilation
Mortality
Group 1, omicron
N = 52,297, cases with Omicron variant infections
Hospital admissions, 235 (0.5%)
Mean follow-up, 5.5 days
88 admitted
ITU, 7
Ventilated, 0
Deaths, 1
Length of hospital stay, 3.4 days (70%) less than delta
Group 2, non – omicron (delta)
N = 16,982, cases with Delta variant infections
Hospital admissions, 222 (1.3%)
Mean follow-up, 15.8 days
189 admitted
ITU, 23
Ventilated, 11
Deaths, 14
Also
Omicron variant infection, reduced risk of hospitalization across age and comorbidity categories
Risk of symptomatic hospitalization was markedly reduced among cases who had tested positive for SARS-CoV-2 infection ≥90 days prior
Intrinsically less severe infection
Less severe in vaccinated and unvaccinated
Evidence for a reduction in severe outcomes among vaccinated cases with both Delta and Omicron variant infections in our study suggests substantial public health benefits from continued COVID-19 vaccination.
Dutch data
Common cold protection
Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts
Cross-reactive immune responses to SARS-CoV-2
52 COVID-19 household contacts
We enumerate the frequency of specific T cells
Spike, nucleocapsid, membrane, envelope and ORF1,
that cross-react with human endemic coronaviruses
Nucleocapsid-specific T cells
Limited protective function of spike-cross-reactive T cells
Our results are thus consistent with,
pre-existing non-spike cross-reactive memory T cells,
protecting SARS-CoV-2-naïve contacts from infection,
thereby supporting the inclusion of non-spike antigens in second-generation vaccines.
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.